Kenneth H. Mayer, Fenway Health
Fenway HealthKenneth Mayer is Medical Research Director at Fenway Health, Professor of Medicine at Harvard Medical School and of Global Health and Population at the Harvard T.C. Chan School of Public Health. He an Infectious Disease Attending at Beth Israel Deaconess Medical Center in Boston
Presenter Of 4 Presentations
Science Workshop
Facilitators
Speaker
Room
Workshop Channel 1
Non-Commercial Satellite
Welcome from the Co-chairs
Session Name
Room
Satellite Channel 4
Non-Commercial Satellite
General Discussion and Q&A
Speaker
- Kenneth H. Mayer, Fenway Health
- Meg Doherty, World Health Organization
- Teodora Elvira Wi, WHO
- Jean-Michel Molina, St-Louis Hospital and University
- Demetre Daskalakis, New York City Department of Health and Mental Hygiene
- Saiqa Mullick, Wits Reproductive Health Institute
- Carolyn Deal, NIAID/NIH
- Rena Janamnuaysook, Thai Red Cross
- Narukjaporn Thammajaruk, Institute of HIV Research and Innovation, Thailand
Session Name
Room
Satellite Channel 4
Non-Commercial Satellite
Summary of meeting by Co-chairs
Session Name
Room
Satellite Channel 4
Moderator Of 1 Session
Non-Commercial Satellite
Room
Satellite Channel 4
Date
Sat, Jul 4, 2020
Time
08:00 AM - 09:00 AM
Session Description
The session aims to highlight the latest data, innovations and examples of good practice in relation to HIV and sexually transmitted infections (STIs), taking into consideration the current COVID-19 pandemic.
Presenter Of 1 Presentation
Symposia session
Conclusion
Speaker
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Moderator Of 1 Session
Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
This session will assess the complexities of HIV prevention trial design in the era of effective PrEP and discuss alternative designs and analytic techniques to help guide the design of future prevention trials. Given the proven efficacy of oral PrEP, the design of studies to determine the efficacy of new prevention technologies has become more complex. This session will be a state-of-the-art update of ongoing HIV prevention trials and new options coming soon into trials. It will explore theoretical and practical issues influencing trial design in an era when effective HIV prevention using oral PrEP is already widely available. This will include the use of different endpoints, new statistical analysis techniques, ethical considerations and practical issues of enrolling and randomizing patients in HIV prevention trials.
Presenter Of 1 Presentation
E-Posters
PEC0615 - Is PEP a gateway to PrEP? Experience from a high volume community health center
Speaker
Session Name
E-posters Track C
Room
Poster Channel - Track C
Presenter Of 1 Presentation
Symposia session
Conclusion
Speaker
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Moderator Of 1 Session
Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
This session will assess the complexities of HIV prevention trial design in the era of effective PrEP and discuss alternative designs and analytic techniques to help guide the design of future prevention trials. Given the proven efficacy of oral PrEP, the design of studies to determine the efficacy of new prevention technologies has become more complex. This session will be a state-of-the-art update of ongoing HIV prevention trials and new options coming soon into trials. It will explore theoretical and practical issues influencing trial design in an era when effective HIV prevention using oral PrEP is already widely available. This will include the use of different endpoints, new statistical analysis techniques, ethical considerations and practical issues of enrolling and randomizing patients in HIV prevention trials.
Presenter Of 6 Presentations
Non-Commercial Satellite
General Discussion and Q&A
Speaker
- Kenneth H. Mayer, Fenway Health
- Meg Doherty, World Health Organization
- Teodora Elvira Wi, WHO
- Jean-Michel Molina, St-Louis Hospital and University
- Demetre Daskalakis, New York City Department of Health and Mental Hygiene
- Saiqa Mullick, Wits Reproductive Health Institute
- Carolyn Deal, NIAID/NIH
- Rena Janamnuaysook, Thai Red Cross
- Narukjaporn Thammajaruk, Institute of HIV Research and Innovation, Thailand
Session Name
Room
Satellite Channel 4
Non-Commercial Satellite
Summary of meeting by Co-chairs
Session Name
Room
Satellite Channel 4
Symposia session
Conclusion
Speaker
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Science Workshop
Facilitators
Speaker
Room
Workshop Channel 1
Non-Commercial Satellite
Welcome from the Co-chairs
Session Name
Room
Satellite Channel 4
E-Posters
Is PEP a gateway to PrEP? Experience from a high volume community health center
Speaker
Session Name
E-posters Track C
Room
Poster Channel - Track C
Moderator Of 2 Sessions
Non-Commercial Satellite
Room
Satellite Channel 4
Session Description
The session aims to highlight the latest data, innovations and examples of good practice in relation to HIV and sexually transmitted infections (STIs), taking into consideration the current COVID-19 pandemic.
Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
This session will assess the complexities of HIV prevention trial design in the era of effective PrEP and discuss alternative designs and analytic techniques to help guide the design of future prevention trials. Given the proven efficacy of oral PrEP, the design of studies to determine the efficacy of new prevention technologies has become more complex. This session will be a state-of-the-art update of ongoing HIV prevention trials and new options coming soon into trials. It will explore theoretical and practical issues influencing trial design in an era when effective HIV prevention using oral PrEP is already widely available. This will include the use of different endpoints, new statistical analysis techniques, ethical considerations and practical issues of enrolling and randomizing patients in HIV prevention trials.